Akebia Therapeutics Inc (AKBA)
1.93
+0.06
(+3.49%)
USD |
NASDAQ |
Nov 08, 15:46
Akebia Therapeutics Revenue (Annual): 194.62M for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 194.62M |
December 31, 2022 | 292.48M |
December 31, 2021 | 211.65M |
December 31, 2020 | 294.64M |
Date | Value |
---|---|
December 31, 2019 | 335.00M |
December 31, 2018 | 207.74M |
December 31, 2017 | 181.23M |
December 31, 2016 | 1.535M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
194.62M
Minimum
2023
335.00M
Maximum
2019
265.68M
Average
292.48M
Median
2022
Revenue (Annual) Benchmarks
Corcept Therapeutics Inc | 482.38M |
Bioventus Inc | 512.34M |
Eli Lilly and Co | 34.12B |
NovaBay Pharmaceuticals Inc | 14.73M |
Palatin Technologies Inc | 4.490M |